Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Acrivon Therapeutics, Inc. (ACRV)

Acrivon Narrows Q2 2026 Net Loss to $18.0 Million From $21.0 Million

Positive Impact 3 of 5 earnings Written later

Acrivon Therapeutics reported a second-quarter 2026 net loss of $18.0 million, down from $21.0 million a year earlier, as research and development and general and administrative expenses declined. The company said its cash, cash equivalents and investments of $90.0 million are expected to fund operations into the fourth quarter of 2027. The company also reiterated that interim data from the ACR-368 Phase 2b study are expected in the second half of 2026.

Key points

  • Net loss per share was $0.43 for the quarter ended June 30, 2026, versus $0.55 a year earlier.
  • Research and development expenses were $13.8 million, versus $16.2 million; the company said two ACR-368 milestones achieved in 2025 did not recur in 2026.
  • General and administrative expenses were $4.8 million, versus $6.5 million, mainly due to lower employee-related expenses, including stock-based compensation.
  • Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026.

The filing

CompanyAcrivon Therapeutics, Inc. (ACRV)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:10 PM ET
Accession number0001193125-26-346859

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.